Covid-19 mRNA疫苗对血清抗苗勒管激素水平的影响
这项前瞻性研究在2021年2月至3月于大学附属三级医疗中心纳入129名18-42岁接种两剂Pfizer-BioNTech Covid-19 mRNA疫苗的育龄女性,比较接种前与接种后3个月血清抗苗勒管激素(AMH)水平。结果显示AMH均值从基线5.3(±SD 4.29)µg/l变为3个月后5.3(±SD 4.50)µg/l(P=0.11),未见显著改变。
要点
- 接种两剂mRNA疫苗后3个月,血清AMH水平未见显著改变(P=0.11)。
- 35岁以上女性各时间点AMH均显著低于年轻女性(P=0.001),但接种前后AMH变化值在三个年龄组间无显著差异(P=0.46)。
- 控制年龄后,免疫应答程度与AMH水平之间未发现关联。
核心结论
- 以血清AMH水平评估的卵巢储备在mRNA SARS-CoV-2疫苗接种后3个月未发生改变。
研究设计与样本
- 前瞻性研究,于2021年2月至3月在大学附属三级医疗中心开展。
- 研究纳入18-42岁接种两剂Pfizer-BioNTech Covid-19疫苗(间隔21天)的育龄女性,排除卵巢功能衰竭、正在接受生育治疗、妊娠期、既往Covid-19感染或已接种疫苗者。
- 研究组共129名接受两剂mRNA疫苗接种的女性。
- 于第一剂mRNA疫苗接种前采集血样检测AMH,3个月后再次采集血样检测AMH及抗Covid-19抗体水平。
- 主要结局定义为AMH水平的绝对变化和百分比变化。
主要发现
- 基线AMH均值为5.3(±SD 4.29)µg/l,3个月后为5.3(±SD 4.50)µg/l(P=0.11)。
- 按年龄分组(<30岁、30-35岁、>35岁)分析显示,35岁以上女性接种前和接种后AMH水平均显著低于年轻女性(P=0.001)。
- 三个年龄组接种前后AMH变化值(Delta AMH)无显著差异(P=0.46)。
- 控制年龄后,免疫应答程度与AMH水平之间未发现关联。
临床怎么用
- 研究结果可为因担心影响未来生育力而对完成Covid-19疫苗接种犹豫的女性提供 reassurance。
局限性
- 尽管为前瞻性设计,出于伦理原因无法事先设置随机未接种对照组。
- 本研究仅检测了第一剂疫苗接种后3个月的血浆AMH水平。
- 可能存在由SARS-CoV-2 mRNA疫苗引起的卵巢和AMH不良变化仅在更晚时间才显现。
- 只有更长期的研究才能探讨这一问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the administration of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine have an association with ovarian reserve as expressed by circulating anti-Müllerian hormone (AMH) levels? SUMMARY ANSWER: Ovarian reserve as assessed by serum AMH levels is not altered at 3 months following mRNA SARS-CoV-2 vaccination. WHAT IS KNOWN ALREADY: A possible impact of SARS-CoV-2 infection or vaccination through an interaction between the oocyte and the somatic cells could not be ruled out, however, data are limited. STUDY DESIGN, SIZE, DURATION: This is a prospective study conducted at a university affiliated tertiary medical center between February and March 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: Study population included reproductive aged women (18-42 years) that were vaccinated by two Pfizer-BioNTech Covid-19 vaccines (21 days apart). Women with ovarian failure, under fertility treatments, during pregnancy, previous Covid-19 infection or vaccinated were excluded from the study. Blood samples were collected for AMH levels before the first mRNA vaccine administration. Additional blood samples after 3 months were collected for AMH and anti-Covid-19 antibody levels. Primary outcome was defined as the absolute and percentage change in AMH levels. MAIN RESULTS AND THE ROLE OF CHANCE: The study group consisted of 129 women who received two mRNA vaccinations. Mean AMH levels were 5.3 (±SD 4.29) µg/l and 5.3 (±SD 4.50) µg/l at baseline and after 3 months, respectively (P = 0.11). To account for possible age-specific changes of AMH, sub-analyses were performed for three age groups: <30, 30-35 and >35 years. AMH levels were significantly lower for women older than 35 years at all times (P = 0.001 for pre and post vaccination AMH levels versus younger women). However, no significant differences for the changes in AMH levels before and after vaccinations (Delta AMH) were observed for the three age groups (P = 0.46). Additionally, after controlling for age, no association was found between the degree of immunity response and AMH levels. LIMITATIONS, REASONS FOR CAUTION: Although it was prospectively designed, for ethical reasons we could not assign a priori a randomized unvaccinated control group. This study examined plasma AMH levels at 3 months after the first vaccination. It could be argued that possible deleterious ovarian and AMH changes caused by the SARS-CoV-2 mRNA vaccinations might take effect only at a later time. Only longer-term studies will be able to examine this issue. WIDER IMPLICATIONS OF THE FINDINGS: The results of the study provide reassurance for women hesitant to complete vaccination against Covid 19 due to concerns regarding its effect on future fertility. This information could be of significant value to physicians and patients alike. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by Sheba Medical Center institutional sources. All authors have nothing to disclose. TRIAL REGISTRATION NUMBER: The study protocol was approved by the 'Sheba Medical Center' Ethical Committee Review Board (ID 8121-21-SMC) on 8 February 2021 and was registered at the National Institutes of Health (NCT04748172).
引用
- Mohr-Sasson A, Haas J, Abuhasira S, et al. The effect of Covid-19 mRNA vaccine on serum anti-Müllerian hormone levels. Hum Reprod. 2022. PMID: 34935913. doi:10.1093/humrep/deab282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。